New angiographic agents with less fibrillatory propensity

Area of Science:

• Cardiology
• Radiology
• Pharmacology

Background:

• Coronary angiography is crucial for diagnosing heart conditions.
• Renografin-76, a commonly used contrast agent, has been shown to decrease the ventricular fibrillation threshold (VFT).
• Newer contrast agents have been developed to potentially improve safety during angiographic procedures.

Purpose of the Study:

• To compare the arrhythmogenic potential of new contrast agents against Renografin-76.
• To evaluate the dose-dependent effects of these agents on the VFT.
• To determine the safety profile of Hexabrix, Exypaque, and Amipaque for cardiac angiography.

Main Methods:

• Anesthetized dogs underwent subselective left circumflex artery injections.
• Ventricular fibrillation threshold (VFT) was measured after administration of varying doses of Renografin-76, Hexabrix, Exypaque, and Amipaque.
• VFT was compared to a control threshold in 115 paired experiments across 25 dogs.

Main Results:

• Renografin-76 significantly lowered the VFT in a dose-dependent manner.
• At low doses, Renografin-76 showed a lower VFT compared to Hexabrix and Exypaque (P < 0.05).
• At higher doses, Renografin-76 exhibited a more pronounced reduction in VFT (32.4%) than Hexabrix (65.7%) and Exypaque (59.2%) (P < 0.001).
• Hexabrix and Exypaque showed no significant difference in VFT at either dose in non-ischemic dogs.
• Amipaque demonstrated a VFT comparable to Hexabrix and Exypaque and was less arrhythmogenic than Renografin-76.

Conclusions:

• Newer contrast agents, including Hexabrix and Exypaque, exhibit a lower propensity to induce ventricular fibrillation compared to Renografin-76.
• These agents appear to offer enhanced safety for cardiac angiographic studies.
• Further research may validate the use of these agents to minimize cardiac risks during angiography.